AFMD Affimed N.V.

3.39
+0.04  (+1%)
Previous Close 3.35
Open 3.36
Price To Book 5.21
Market Cap 211630649
Shares 62,427,920
Volume 227,546
Short Ratio
Av. Daily Volume 515,411

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data at ASH noted 46% CR; 88% ORR.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
AFM13
Hodgkin Lymphoma - Cancer
Phase 1b/2a data at ASH 2018 noted 4/9 ORs including 1CR.
AFM13
CD30-positive lymphoma
Phase 1 trial placed on clinical hold - October 8, 2018.
AFM11
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)
Phase 2 trial to be initiated 1H 2019.
AFM13
Relapsed/refractory peripheral T cell lymphoma (PTCL); transformed mycosis fungoides (TMF)